Under current Department of Defense (DOD) directive, the laboratories certified to conduct urinalyis testing in support of the DOD Drug Deterrence Program are required to conduct all-isomer analysis on all specimens that confirm at a concentration greater than 500 ng/mL methamphetamine (METH). Although the same cutoff concentration is required for amphetamine (AMP) reporting, there is no requirement for dl-isomer analysis of AMP-positive specimens. Of the 894,823 specimens screened by the Army Drug Testing Laboratory at Ft. Meade, MD during a 19-month period, 339 confirmed positive for METH. From this positive population, seven specimens failed to confirm at or above the DOD cutoff of > 20% d-isomer. One of the seven specimens contained 534 ng/mL /-AMP and was reported positive for AMP. Although 100% of the AMP was the/-isomer, under current DOD directive, this information was not passed along to the Medical Review Officers (MRO) to assist them during the interview process. Although this situation appears to be a rare event, consideration should be given to requiring dl-isomer analysis of AMP-positive specimens and forwarding this information to the MRO. 
Introduction
AMP. Additionally, the directive requires confirmation testing for METH analogues; 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxymethamphetamine (MDMA), and 3,4-methylenedioxyethamphetamine (MDEA).
The requirement for confirmation greater than 20% d-METH isomer was provided to prevent false-positive METH results identified in urine specimens from individuals taking prescription medications that metabolize to METH or contain I-METH or a racemic mixture. The directive was also aimed at preventing false-positive METH results from individuals using the nonprescription Vicks Inhalers | that contain only I-METH.
Apparently, the framers of the directive did not believe that a positive l-AMP result greater than 500 mg/mL would occur from the use of an/-METH product.
Based on DOD guidelines, the laboratory provides the analysis information to a Medical Review Officer (MRO), who performs an interview and medical review prior to making a final determination. Although the guidance provided by the current directive may be adequate for the vast majority of AMP result interpretations during MRO reviews, a recent observation by our laboratory suggests that additional information may be helpful to the MRO in some rare situations.
The Ft. Meade Forensic Toxicology Drug Testing Laboratory (FTDTL) is one of two Army laboratories certified to perform urinalysis drug testing in support of the Department of Defense (DOD) Drug Deterrence Program. Effective June 1, 1997, the FTDTL received a DOD directive regarding testing procedures and reporting requirements of amphetamines (AMP). The directive stated that the criteria for reporting a positive methamphetamine (METH) would be that the specimen must contain total METH stereoisomers in a concentration greater than 500 ng/mL and must contain d-METH at a concentration greater than 20% of the total stereoisomers of METH present. For AMP it directed that all specimens containing 500 ng/mL or more of total AMP stereoisomers would be reported positive for
MDA-d5, and dI-MDEA-d6 were purchased from Radian Corp. l-AMP and I-METH were purchased from Alltech Corp. Optical purity of 98% or greater for these standards was certified by the manufacturer. Dimethylformamide, heptafluorobutyricanhydride and S(-)-N-trifluoroacetyl-L-prolyl chloride were obtained from EM Science Industries, Inc., Sigma Corp., and Regis Technologies, respectively. Methanol, ethyl acetate, methylene chloride, isopropanol, and chloroform were Mallinckrodt highperformance liquid chromatography grade.
Procedures
After accessioning the specimens, an aliquot (approximately 2 mL) was poured from the specimen bottle and tested using an Olympus AU800 (Olympus America Inc., Melville, NY). The initial screening analysis was performed using a kinetic interaction of microparticles (Abuscreen Online, Roche Diagnostics Systems, Somerville, NJ). At the 500-ng/mL cutoff, the assay was designed to report as positive for urine samples containing either 500 ng/mL of AMP or 500 ng/mL METH. Additionally, 4.0 mL of a 0.4M sodium metaperiodate solution was added to each 85-mL bottle of microparticle reagent supplied by the manufacturer. The addition of the metaperiodate is to prevent the cross-reactivity of ephedrine, pseudoephedrine, and phenylpropanolamine that may be present because of over-the-counter cold medication (1) .
After a presumptive positive initial screen result, a second aliquot was obtained from the specimen bottle and a re-screen performed using a homogenous enzyme immunoassay technique (Emit [I, Syva Co., Cupertino, CA) on the AU800. This methodolgy has been shown to have a low cross-reactivity with prescription drugs (fenfluramine) commonly used for weight control.
Subsequent to a presumptive positive from the re-screen assays, a third aliquot was obtained and prepared for confirmation testing. AMP and METH were extracted using a liquid-liquid extraction and derivatization method described by Cody and Schwarzhoff (2) . Briefly, 100 IJL of AMP/METH internal standard (15,000 ng/mL dI-METH-dlJ15,000 ng/mL all-AMP-d5) was added to either 3.0-mL specimen or a diluted specimen to a volume of 3.0 mL. After the addition of 1.0 mL 1M NaOH, 20 mL of 5% (v/v) isopropanol in methylene chloride was added and shaken for 3 rain. After aspirating the upper layer to waste, 2.0 mL of 0.1M H2SO 4 was added. Tubes were shaken for 3 rain, and the upper aqueous layer was transferred to a clean tube. Three drops of saturated KOH were added, followed by 2.0 mL methylene chloride. Tubes were vortex mixed for I min, and the upper layer was aspirated to waste. The lower layer was derivatized with 100 pL 5% dimethylformamide (1 mL of concentration HCI mixed with 99 mL methyl alcohol then added to dimethylformamide, 95:5), 35 pL of heptafluorobutyricanhydride, and 100 pL of ethyl acetate. Specimens were evaporated to dryness under nitrogen and reconstituted with 1 mL of ethyl acetate.
The gas chromatographic-mass spectrometric (GC-MS) analysis was completed on a Hewlett-Packard 6890 GC/5973 MSD using an HP Ultra 2 12-m x 0.2-ram (5% phenyl methyl siloxane) capillary column. Specimens were injected in splitless mode with an injection-port temperature of 200~ final oven temperature of 200~ and a detector temperature of 280~ Quantitating and qualifier ions for AMP internal standard and AMP were 244/240, 123/118, and none/91, respectively. Quantitating and two qualifier ions for METH internal standard/METH were 260/254, 213/210, and none/118, respectively.
The isomeric forms of the AMP and METH were separated by following the extraction protocol described and preparing derivatives by adding 20 IJL of the chiral reagent, 0.1M S(-)-Ntrifluoroacetyl-L-prolyl chloride, catalyzed by 10 pL triethylamine followed by 300 pL methanol to decompose the excess derivatizing reagent. After evaporation under nitrogen, derivatized extracts were reconstituted with 100 pL ethyl acetate.
Results and Discussion
During the September 1997 to April 1999 timeframe, the laboratory screened a total of 894,823 active-duty military specimens for AMP. The testing of this population produced 339 screened and confirmed positives for METH at concentrations greater than the 500-ng/mL cutoff. Of the 339 confirmed positives for METH, 332 contained d-METH at a concentration > 20% d isomer. There were seven specimens that did not meet the requirements for d-METH analysis and were reported negative for METH (Table I) .
Five of the seven negative specimens confirmed positive for METH analogues. The presence of METH in the urine was most likely due to "contamination" of the ingested analogue or produced from metabolism. Specimen D fits the profile of normal Vicks inhaler usage as described by Fitzgerald et al. (3) . In this controlled study, three subjects were instructed to inhale the medication every 20 min for 6 h. Urine samples were collected over the subsequent 80 h and analyzed by GC-MS for I-METH and total AMP. One subject reached a peak concentration for I-METH of 6000 ng/mL. Levels of AMP ranged from 250 to 455 ng/mL with [AMP]/[METH] less than 0.08.
An additional explanation for these results could be explained by ingestion of a prescription drug such as selegiline. Selegiline is a monoamine oxidase inhibitor often prescribed to control Parkinsons Disease (4). Urinalyses of subjects taking selegiline showed excretion of only the/form of AMP and METH (5) . Given the fact that the study involved only four specimens and provides no information concerning the dose ingested or urinalysis time after ingestion, I-METH concentrations ranged from 829 to 4690 ng/mL with [AMP]/[METH] ranging from 0.37 to 0.42. Specimen H is more difficult to explain. The total METH concentration is above the normal concentration reported for routine use of Vicks inhaler. The [AMP]/[METH} of 0.03 would argue against selegiline ingestion. Of particular concern is the fact that although the d-METH analysis resulted in a negative report for METH, the laboratory reported the specimen positive for AMP based on current DOD criteria.
There is no provision under the current DOD directive to report the isomeric form of the AMP result. The laboratory reported specimen H positive for AMP and negative for METH. Thus, the MRO who had to interpret the result for specimen H was faced with a difficult task. This case is further complicated by the fact that the specimen was from a soldier stationed in a European country. It is generally accepted that in Europe, the illicit production of AMP far exceeds that of METH. Upon further investigation (personal communication), it was disclosed that the individual who provided specimen H admitted to illegal AMP use.
Although the occurrence of a specimen containing a high concentration of licit METH while confirming positive for l-AMP appears to be a rare event, consideration should be given to requiring all-isomer analysis of AMP-positive specimens and forwarding this information to the MRO. This information would also assist the MRO when determining possible use of prescription drugs such as clobenzorex that metabolize to/-AMP.
